Close Menu
Home › Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

Mar 12, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it has partnered with Bristol-Myers Squibb to develop a companion diagnostic for a number of cancer immunotherapies, with an initial focus on colorectal cancer (CRC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. Qiagen Says It Is Fielding Acquisition Offers

  2. Employee Benefits Programs Share Early Experiences Implementing Genetic Testing

    Premium

  3. Centogene to Provide Diagnostic Testing Services for PTC Therapeutics Gene Therapy Program

  4. Qiagen Upgraded to Overweight by JP Morgan; Stock Surges on Thermo Fisher Buyout Speculation

  5. Exact Sciences Sues Johns Hopkins University for 'Improperly' Demanding Royalties

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.